|
October 2007
Quality of life is key to cancer survival - study
October 31, 2007
CHICAGO (Reuters Life!) - Having someone to drive you to cancer treatments or make sure you are eating may be even more important than tumor size or other medical factors in predicting cancer survival, U.S. researchers said on Tuesday.
Denosumab on par with current therapies for cancer-related bone loss
October 30, 2007
NEW YORK (Reuters Health) - The experimental drug denosumab seems to work at least as well as bisphosphonate therapy in limiting bone turnover in patients with breast cancer metastatic to bone, according to results of a randomized active-controlled phase II study.
Tasigna Approved for Gleevec-Resistant Chronic Myeloid Leukemia
October 29, 2007
The Food and Drug Administration approved Tasigna (nilotinib) as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Gleevec (imatinib), an established treatment standard.
Axitinib shows promise in kidney cancer
October 29, 2007
NEW YORK (Reuters Health) - Axitinib has promising activity and manageable toxicity in patients with metastatic cytokine-refractory renal cell cancer, according to study results released today and published in the November issue of The Lancet Oncology.
IL-21 may improve efficacy of sorafenib for metastatic renal cell cancer
October 26, 2007
NEW YORK (Reuters Health) - The preliminary results of a phase I study suggest that combined treatment with sorafenib (Nexavar) and interleukin-21 is superior to sorafenib alone in patients with metastatic renal cell carcinoma.
Panel urges psych screening in cancer patients
October 24, 2007
WASHINGTON (Reuters) - Doctors treating cancer patients should try harder to help them deal with the emotional toll the disease exacts, an expert panel said on Tuesday. Marked rise in contralateral prophylactic mastectomies seen in US
October 23, 2007
NEW YORK (Reuters Health) - From 1998 through 2003, the rate of bilateral mastectomies among women with cancer in one breast more than doubled, according to a report in the October 22nd online issue of the Journal of Clinical Oncology. Taxane chemotherapy supported for early breast cancer
October 23, 2007
NEW YORK (Reuters Health) - Adjuvant chemotherapy regimens that use taxanes improve the overall and disease-free survival of women with operable early breast cancer, according to a report in The Cochrane Library released October 16.
Avastin active against aggressive brain tumor
October 19, 2007
WASHINGTON (Reuters) - Genentech Inc colon and lung cancer drug Avastin, along with standard chemotherapy, increases survival rates of patients with a very deadly type of brain tumor, according to the results of a small pilot study.
Breast cancer survivors: keep heart health in mind
October 19, 2007
NEW YORK (Reuters Health) - Authors of a report released this week encourage women who survive breast cancer to address all of the modifiable risk factors they have for heart disease, because breast cancer therapy can damage the heart.
Some breast cancers don't respond to chemotherapy
October 19, 2007
NEW YORK (Reuters Health) - An analysis of the results of several studies confirm previous reports suggesting that chemotherapy offers little or no survival benefits for young women with estrogen receptor (ER)-positive breast cancers and, if given, it should not be the sole second-phase, or "adjuvant" therapy.
FDA approves new drug for advanced breast cancer
October 17, 2007
WASHINGTON (Reuters) - A new drug called Ixempra for women with advanced breast cancer that does not respond to other therapies has won U.S. approval to be sold and is expected to be available in days, according to Bristol-Myers Squibb Co.
More whites than blacks get breast cancer chemo
October 16, 2007
NEW YORK (Reuters Health) - For many different reasons, African American women do not receive add-on therapy after breast cancer as often as white American women do, a new study shows. Cancer death rates continue to fall
October 15, 2007
WASHINGTON (Reuters) - Death rates from cancer continue to fall in the United States, dropping more than 2 percent per year from 2002 through 2004, cancer experts reported on Monday.
Yoga can give women with breast cancer a boost
October 15, 2007
NEW YORK (Reuters Health) - Special yoga classes can significantly improve the quality of life and well being of women with breast cancer patients -- particularly those who are not taking chemotherapy -- a new study shows.
Exercise can ease some aspects of chemotherapy
October 15, 2007
NEW YORK (Reuters Health) - For women undergoing chemo for breast cancer, an exercise program doesn't do much to improve their quality of life -- but it can boost their self-esteem, physical fitness, and chemotherapy completion rates. Cancer treatment may raise later pregnancy risks
October 15, 2007
NEW YORK (Reuters Health) - Pregnant women who are cancer survivors may face an increased risk of certain complications, including bleeding after delivery and premature birth, according to a UK study. Low-fat diet may lower ovarian cancer risk
October 9, 2007
NEW YORK (Reuters Health) - Long-term adherence to a low-fat diet may reduce the risk of ovarian cancer, according to the results of the Women's Health Initiative Dietary Modification trial, which involved nearly 50,000 postmenopausal women.
Surgery offers
best survival for prostate cancer
October 8, 2007
NEW YORK (Reuters Health) - Removal of the prostate gland, a surgical procedure also known as "prostatectomy," offers longer survival rates than radiation therapy, careful monitoring, or hormone therapy for men with "localized" prostate cancer, a common form of the disease in which the cancer has not yet spread to other organs, new research shows.
Prostate cancer no more aggressive in black men than white men
October 4, 2007
NEW YORK (Reuters Health) - A new study refutes the long-held belief that African-American men have more aggressive prostate cancer tumors than Caucasian men.
Treatment-related AML and MDS rates "acceptably low" after radiotherapy for NHL
October 4, 2007
NEW YORK (Reuters Health) - Following radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma (NHL), the incidence of treatment-related acute myelogenous leukemia (t-AML) and myelodysplastic syndrome (t-MDS) is 2.5% after 5 years, researchers report.
Thalidomide improves survival of multiple myeloma in elderly patients
October 4, 2007
NEW YORK (Reuters Health) - In elderly patients with multiple myeloma, adding thalidomide to melphalan plus prednisone (MP), the standard therapy for the disease, can significantly improve overall survival, according to a report in the October 6th issue of The Lancet.
Broader US label for colorectal cancer drug Erbitux
October 3, 2007
NEW YORK (Reuters) - ImClone Systems Inc and Bristol-Myers Squibb Co said on Tuesday that U.S. regulators had approved a broadened label for their Erbitux drug to include survival data for its use as a single agent for advanced colorectal cancer patients who failed other drugs.
Low-dose tamoxifen attenuates risk biomarkers in HRT users
October 3, 2007
NEW YORK (Reuters Health) - Tamoxifen at low doses favorably modulates biomarkers of breast cancer and cardiovascular risk in women who use hormone replacement therapy (HRT) without increasing endometrial proliferation or menopausal symptoms, according to a study published in the September issue of the Journal of Clinical Oncology.
High white cell count may predict cancer: study
October 3, 2007
NEW YORK (Reuters Health) - Postmenopausal women with elevated white blood cell (WBC) counts appear to be at increased risk of developing certain types of cancer, including breast, colorectal, endometrial, and lung cancers, a new study shows.
|
